Investigate / GILD
Understand GILEAD SCIENCES, INC.
Can Gilead keep its HIV franchise competitive while its oncology and other pipeline efforts mature?
Snapshot reviewed 2026-10-02. Source published 2026-08-06. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / GILD
Ask better questions. Keep the evidence.
Explore the available sources for GILEAD SCIENCES, INC., then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
Gilead develops medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
Latticework interpretation
What could support the case?
If subsequent regulatory decisions permit the bictegravir and lenacapavir regimen and it gains adoption, the filing’s HIV development effort could support the franchise; approval and commercial outcomes need verification.
Latticework interpretation
What could break the case?
Gilead receives a substantial portion of revenue from HIV products and may be unable to sustain or grow sales if competing products, including generics, gain share or new medications fail to arrive.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Gilead develops medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $7,803m | $7,082m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | −$10,394m | $2,474m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | −$10,496m | $1,960m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $6,117m | $2,584m |
Comparison caveat: Current losses include large acquired research-and-development charges associated with Ouro Medicines, Tubulis and Arcellx. They are not solely a decline in recurring product demand. Operating cash shown covers the half-year.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If subsequent regulatory decisions permit the bictegravir and lenacapavir regimen and it gains adoption, the filing’s HIV development effort could support the franchise; approval and commercial outcomes need verification.
Supporting filing ↗The strongest caution
Gilead receives a substantial portion of revenue from HIV products and may be unable to sustain or grow sales if competing products, including generics, gain share or new medications fail to arrive.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How dependent is revenue on HIV products?
Starting evidence: A substantial portion of revenue comes from HIV treatment and prevention products, so concentration could amplify competitive or pricing pressure.
Investigate next: Review the product revenue breakdown and how its HIV share has changed across reported periods.
Read the supporting filing ↗Can new HIV filings extend the franchise?
Starting evidence: The FDA accepted an NDA for bictegravir and lenacapavir in virologically suppressed people with HIV under priority review.
Investigate next: Verify the subsequent FDA decision and approved labeling first, then compare the regimen with existing therapies; do not assume the filing’s review status remains current.
Read the supporting filing ↗Will cell therapy operations stay reliable and accepted?
Starting evidence: CAR T-cell therapies depend on third-party apheresis centers, shippers, couriers and hospitals, so disruptions could affect delivery to patients.
Investigate next: Examine disclosures on manufacturing capacity, supply disruptions, safety labeling and reimbursement for Yescarta and Tecartus.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.